FDA grants orphan drug status to an experimental drug for squamous NSCLC

[MFH_Advocate]

An experimental drug called, veliparib, is being studied for treatment of patients with squamous NSCLC. This drug is a "PARP" inhibitor and may be used with chemotherapy or radiation to help improve efficacy. Although it's too early to tell if this drug will be FDA-approved, the possibility of having another treatment option is exciting news. A press release can be found here: biospace.com/News/abbvie-re...